IP Library › Granted Patent US 12,697,385
Granted Patent B2
US 12,697,385 · App. 17/224,865 · Granted Aug 4, 2026

Combination therapy for cancer with anti-B7-H4 antibodies and anti-PD-1 antibodies

Inventors: Sandeep P. Inamdar (South San Francisco, CA); Helen L. Collins (South San Francisco, CA); Hong Xiang (South San Francisco, CA); Xiang Zhang (South San Francisco, CA); Neyssa Marina (South San Francisco, CA)
Assignee: FIVE PRIME THERAPEUTICS, INC.
A61K39/3955A61P35/00A61K39/00A61K2039/505A61K2039/507A61K2039/545C07K16/2818C07K16/2827C07K2317/24C07K2317/41C07K2317/51C07K2317/515C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,385
App. No.
17/224,865
Granted
Aug 4, 2026
Kind
B2
Abstract

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.

Claims (51)

1 . A method of treating a solid tumor in a human subject, the method comprising administering to the subject

(i) about 0.1 to about 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10; and

(ii) about 200 mg of an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:38, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:39.

2 . The method of claim 1 , wherein about 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

3 . The method of claim 1 , wherein about 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

4 . The method of claim 1 , wherein about 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

5 . The method of claim 1 , wherein about 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

6 . The method of claim 1 , wherein about 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

7 . The method of claim 1 , wherein about 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

8 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered concurrently.

9 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered sequentially.

10 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is administered about once every three weeks.

11 . The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered about once every three weeks.

12 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are each administered about once every three weeks.

13 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and/or a VL comprising the amino acid sequence set forth in SEQ ID NO: 12.

14 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain constant region and/or a light chain constant region.

15 . The method of claim 14 , wherein the heavy chain constant region is a human immunoglobulin IgG1 heavy chain constant region and/or wherein the light chain constant region is a human immunoglobulin IgGκ light chain constant region.

16 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:25 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:23.

17 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and/or a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

18 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.

19 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a full length antibody.

20 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is an antigen-binding fragment.

21 . The method of claim 20 , wherein the antigen-binding fragment comprises a Fab, Fab′, F(ab′) 2 , single chain Fv (scFv), disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGΔCH2, minibody, F(ab′) 3 , tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb 2 , (scFv) 2 , or scFv-Fc.

22 . The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence SEQ ID NO:33.

23 . The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab.

24 . The method of claim 1 , the method comprising administering to the subject

(i) 3, 10 or 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and a VL comprising the amino acid sequence set forth in SEQ ID NO: 12, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is not detectably fucosylated; and

(ii) 200 mg of pembrolizumab;

wherein (i) and (ii) are administered intravenously as separate formulations on the same day.

25 . The method of claim 24 , wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

26 . The method of claim 1 , the method comprising administering to the subject

(i) about 20 mg/kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) about 200 mg of an anti-PD-1 antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously about once every three weeks.

27 . The method of claim 26 , wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

28 . The method of claim 26 , wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

29 . The method of claim 27 , wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

30 . The method of claim 1 , wherein the solid tumor is selected from the group consisting of breast cancer, ductal carcinoma, endometrial carcinoma, ovarian cancer, urothelial cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer.

31 . The method of claim 30 , wherein the solid tumor is triple negative breast cancer.

32 . The method of claim 30 , wherein the solid tumor is a hormone-receptor (HR)-positive breast cancer.

33 . The method of claim 30 , wherein the non-small cell lung cancer is squamous cell carcinoma.

34 . The method of claim 1 , wherein the patient has not received prior therapy with a PD-1/PD-L1 antagonist.

35 . The method of claim 1 , wherein the method further comprises monitoring the number of immune cells in the tumor and/or monitoring cytokine levels in the subject.

36 . The method of claim 1 , wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is present in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies or antigen-binding fragments thereof in the composition are afucosylated.

37 . The method of claim 36 , wherein fucosylation of the anti-B7-H4 antibody or antigen-binding fragment thereof is undetectable in the composition.

38 . The method of claim 36 , the method comprising administering to the subject

(a) a pharmaceutical composition comprising (i) anti-B7-H4 antibodies that specifically bind to human B7-H4 and comprise a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12 and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies thereof in the composition are afucosylated, and wherein about 20 mg/kg of the antibodies are administered; and

(b) a pharmaceutical composition comprising an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33 and a pharmaceutically acceptable excipient, wherein about 200 mg of the antibody or antigen-binding fragment thereof is administered,

wherein (a) and (b) are administered intravenously about once every three weeks.

39 . The method of claim 38 , wherein the anti-B7-H4 antibodies comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

40 . The method of claim 38 , wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

41 . The method of claim 39 , wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2021
From: INAMDAR, SANDEEP P.; COLLINS, HELEN L.; XIANG, HONG; ZHANG, XIANG; MARINA, NEYSSA
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 056537/0914 →
Continuity (5)
Continuation PCTUS2019056210 · Oct 15, 2019
Provisional Application 62854494 · May 30, 2019
Provisional Application 62802091 · Feb 6, 2019
Provisional Application 62745464 · Oct 15, 2018
Related Publication 20210332137A1 · Oct 28, 2021
References Cited (400)
US 3817837A · Rubenstein et al. · 1974 [cited by applicant]
US 3850752A · Schuurs et al. · 1974 [cited by applicant]
US 3939350A · Kronick et al. · 1976 [cited by applicant]
US 3996345A · Ullman et al. · 1976 [cited by applicant]
US 4275149A · Litman et al. · 1981 [cited by applicant]
US 4277437A · Maggio · 1981 [cited by applicant]
US 4366241A · Tom et al. · 1982 [cited by applicant]
US 4472509A · Gansow et al. · 1984 [cited by applicant]
US 4938948A · Ring et al. · 1990 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5196066A · Kusuda et al. · 1993 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5516637A · Huang et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5585097A · Bolt et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5672694A · Campbell et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5693780A · Newman et al. · 1997 [cited by applicant]
US 5698426A · Huse · 1997 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750753A · Kimae et al. · 1998 [cited by applicant]
US 5780225A · Wigler et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5965726A · Pavlakis et al. · 1999 [cited by applicant]
US 5969108A · Mccafferty et al. · 1999 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6174666B1 · Pavlakis et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277022B1 · Melin · 2001 [cited by applicant]
US 6291664B1 · Pavlakis et al. · 2001 [cited by applicant]
US 6414132B1 · Pavlakis et al. · 2002 [cited by applicant]
US 6602684B1 · Umana et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6794498B2 · Pavlakis et al. · 2004 [cited by applicant]
US 6891030B2 · Chen · 2005 [cited by applicant]
US 6946292B2 · Kanda et al. · 2005 [cited by applicant]
US 7214775B2 · Hanai et al. · 2007 [cited by applicant]
US 7304149B2 · Murphy et al. · 2007 [cited by applicant]
US 7504256B1 · Ogawa et al. · 2009 [cited by applicant]
US 7619068B2 · Pilkington et al. · 2009 [cited by applicant]
US 7622565B2 · Chen · 2009 [cited by applicant]
US 7658921B2 · Dall et al. · 2010 [cited by applicant]
US 7687061B2 · Hanai et al. · 2010 [cited by applicant]
US 7709226B2 · Foote · 2010 [cited by applicant]
US 7875702B2 · Chen · 2011 [cited by applicant]
US 7888477B2 · Bangur et al. · 2011 [cited by applicant]
US 7931896B2 · Chen · 2011 [cited by applicant]
US 7964195B2 · Papkoff et al. · 2011 [cited by applicant]
US 8129347B2 · Chen · 2012 [cited by applicant]
US 8182813B2 · Brasel et al. · 2012 [cited by applicant]
US 8206715B2 · Wong et al. · 2012 [cited by applicant]
US 8236767B2 · Chen · 2012 [cited by applicant]
US 8263079B2 · Doody et al. · 2012 [cited by applicant]
US 8323645B2 · Veiby et al. · 2012 [cited by applicant]
US 8444971B2 · Papkoff et al. · 2013 [cited by applicant]
US 8513199B2 · Brasel et al. · 2013 [cited by applicant]
US 8591886B2 · Ponath et al. · 2013 [cited by applicant]
US 8609816B2 · Korman et al. · 2013 [cited by applicant]
US 8652465B2 · Freeman et al. · 2014 [cited by applicant]
US 8703916B2 · Chen · 2014 [cited by applicant]
US 8759490B2 · Veiby et al. · 2014 [cited by applicant]
US 8906369B2 · Papkoff et al. · 2014 [cited by applicant]
US 9005616B2 · Langermann et al. · 2015 [cited by applicant]
US 9011853B2 · Langermann et al. · 2015 [cited by applicant]
US 9121853B2 · Kwon et al. · 2015 [cited by applicant]
US 9221910B2 · Fertig et al. · 2015 [cited by applicant]
US 9279008B2 · Scholler et al. · 2016 [cited by applicant]
US 9296822B2 · Korman et al. · 2016 [cited by applicant]
US 9421277B2 · Veiby et al. · 2016 [cited by applicant]
US 9422351B2 · Scholler et al. · 2016 [cited by applicant]
US 9447186B2 · Zang et al. · 2016 [cited by applicant]
US 9555124B2 · Chen · 2017 [cited by applicant]
US 9562099B2 · Leong et al. · 2017 [cited by applicant]
US 9574000B2 · Langermann et al. · 2017 [cited by applicant]
US 9676854B2 · Liu et al. · 2017 [cited by applicant]
US 9926378B2 · Veiby et al. · 2018 [cited by applicant]
US 9957312B2 · Langermann et al. · 2018 [cited by applicant]
US 10059768B2 · Leong et al. · 2018 [cited by applicant]
US 11306144B2 · Kaplan et al. · 2022 [cited by applicant]
US 11814431B2 · Kaplan · 2023 [cited by examiner]
US 20030055224A1 · Gao et al. · 2003 [cited by applicant]
US 20030060612A1 · Goddard et al. · 2003 [cited by applicant]
US 20030165504A1 · Retter et al. · 2003 [cited by applicant]
US 20030181692A1 · Ni et al. · 2003 [cited by applicant]
US 20030208058A1 · Fiscella et al. · 2003 [cited by applicant]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20040126807A1 · Goddard et al. · 2004 [cited by applicant]
US 20050163772A1 · Dong et al. · 2005 [cited by applicant]
US 20060088523A1 · Andya et al. · 2006 [cited by applicant]
US 20060223077A1 · Ni et al. · 2006 [cited by applicant]
US 20060253928A1 · Bakker et al. · 2006 [cited by applicant]
US 20070036783A1 · Humeau et al. · 2007 [cited by applicant]
US 20070178551A1 · Gerngross · 2007 [cited by applicant]
US 20070218032A1 · Kwon et al. · 2007 [cited by applicant]
US 20070248600A1 · Hansen et al. · 2007 [cited by applicant]
US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]
US 20080060092A1 · Dickey et al. · 2008 [cited by applicant]
US 20080206235A1 · Chen · 2008 [cited by applicant]
US 20090005301A1 · Ni et al. · 2009 [cited by applicant]
US 20090118175A1 · Macina · 2009 [cited by applicant]
US 20090176317A1 · Kwon et al. · 2009 [cited by applicant]
US 20090226530A1 · Lassner et al. · 2009 [cited by applicant]
US 20110020325A1 · Kwon et al. · 2011 [cited by applicant]
US 20110085970A1 · Terrett et al. · 2011 [cited by applicant]
US 20120014947A1 · Fu · 2012 [cited by applicant]
US 20130078234A1 · Takahashi et al. · 2013 [cited by applicant]
US 20140037551A1 · Zang et al. · 2014 [cited by applicant]
US 20140294861A1 · Scholler et al. · 2014 [cited by applicant]
US 20140322129A1 · Leong et al. · 2014 [cited by applicant]
US 20140335541A1 · Kwon et al. · 2014 [cited by applicant]
US 20140356364A1 · Liu et al. · 2014 [cited by applicant]
US 20140364585A1 · Zhang et al. · 2014 [cited by applicant]
US 20150315275A1 · Liu et al. · 2015 [cited by applicant]
US 20160017040A1 · Leong et al. · 2016 [cited by applicant]
US 20160146806A1 · Langermann et al. · 2016 [cited by applicant]
US 20160159910A1 · Leong et al. · 2016 [cited by applicant]
US 20160185870A1 · Van et al. · 2016 [cited by applicant]
US 20160304581A1 · Zang et al. · 2016 [cited by applicant]
US 20160304607A1 · Sadineni et al. · 2016 [cited by applicant]
US 20170015758A1 · Hammond et al. · 2017 [cited by applicant]
US 20170029525A1 · Zang et al. · 2017 [cited by applicant]
US 20170044259A1 · Tipton et al. · 2017 [cited by applicant]
US 20170044268A1 · Gurney et al. · 2017 [cited by applicant]
US 20170143827A1 · Sadineni et al. · 2017 [cited by applicant]
US 20170158771A1 · Glennie et al. · 2017 [cited by applicant]
US 20170204185A1 · Chen · 2017 [cited by applicant]
US 20170233808A1 · Haining et al. · 2017 [cited by applicant]
US 20170334999A1 · Sathyanarayanan · 2017 [cited by examiner]
US 20180106862A1 · Whetsel · 2018 [cited by applicant]
US 20180106864A1 · Moeneclaey · 2018 [cited by applicant]
US 20180118831A1 · Epstein et al. · 2018 [cited by applicant]
US 20180186878A1 · Rosenthal · 2018 [cited by applicant]
US 20190085080A1 · Kaplan et al. · 2019 [cited by applicant]
US 20200081497A1 · Hung et al. · 2020 [cited by applicant]
US 20200255528A1 · Kaplan et al. · 2020 [cited by applicant]
US 20210070861A1 · Quan et al. · 2021 [cited by applicant]
US 20210070862A1 · Inamdar et al. · 2021 [cited by applicant]
US 20210079096A1 · Kaplan et al. · 2021 [cited by applicant]
US 20240043542A1 · Kaplan et al. · 2024 [cited by applicant]
CN 101951959A · 2011 [cited by applicant]
CN 104945508A · 2015 [cited by applicant]
CN 106804108A · 2017 [cited by applicant]
CN 107299085A · 2017 [cited by applicant]
CN 107405401A · 2017 [cited by applicant]
CN 111094352A · 2020 [cited by applicant]
CN 111868089A · 2020 [cited by applicant]
CN 111971308A · 2020 [cited by applicant]
EP 1331266A1 · 2003 [cited by applicant]
SG 162030A1 · 2010 [cited by applicant]
WO 198605807A1 · 1986 [cited by applicant]
WO 198901036A1 · 1989 [cited by applicant]
WO 199002809A1 · 1990 [cited by applicant]
WO 199110737A1 · 1991 [cited by applicant]
WO 199201047A1 · 1992 [cited by applicant]
WO 199218619A1 · 1992 [cited by applicant]
WO 199311236A1 · 1993 [cited by applicant]
WO 199429351A2 · 1994 [cited by applicant]
WO 199515982A2 · 1995 [cited by applicant]
WO 199520401A1 · 1995 [cited by applicant]
WO 199713844A1 · 1997 [cited by applicant]
WO 199734631A1 · 1997 [cited by applicant]
WO 199823289A1 · 1998 [cited by applicant]
WO 199954342A1 · 1999 [cited by applicant]
WO 200036107A2 · 2000 [cited by applicant]
WO 200042072A2 · 2000 [cited by applicant]
WO 200061739A1 · 2000 [cited by applicant]
WO 200129246A1 · 2001 [cited by applicant]
WO 200140269A2 · 2001 [cited by applicant]
WO 200162891A2 · 2001 [cited by applicant]
WO 200202587A1 · 2002 [cited by applicant]
WO 200206317A2 · 2002 [cited by applicant]
WO 200210187A1 · 2002 [cited by applicant]
WO 200216581A2 · 2002 [cited by applicant]
WO 200230954A1 · 2002 [cited by applicant]
WO 200231140A1 · 2002 [cited by applicant]
WO 200260919A2 · 2002 [cited by applicant]
WO 200271928A2 · 2002 [cited by applicant]
WO 200304989A2 · 2003 [cited by applicant]
WO 200262203A3 · 2003 [cited by applicant]
WO 200376579A2 · 2003 [cited by applicant]
WO 200311878A3 · 2003 [cited by applicant]
WO 200397802A2 · 2003 [cited by applicant]
WO 200397803A2 · 2003 [cited by applicant]
WO 2003104399A2 · 2003 [cited by applicant]
WO 2003104438A2 · 2003 [cited by applicant]
WO 2004000221A2 · 2003 [cited by applicant]
WO 2004058167A2 · 2004 [cited by applicant]
WO 2004065540A2 · 2004 [cited by applicant]
WO 2004101756A2 · 2004 [cited by applicant]
WO 2004113500A2 · 2004 [cited by applicant]
WO 2005035724A2 · 2005 [cited by applicant]
WO 2005051990A2 · 2005 [cited by applicant]
WO 2005052121A2 · 2005 [cited by applicant]
WO 2005062788A2 · 2005 [cited by applicant]
WO 2003101400A3 · 2005 [cited by applicant]
WO 2006053110A2 · 2006 [cited by applicant]
WO 2006074418A2 · 2006 [cited by applicant]
WO 2006098887A2 · 2006 [cited by applicant]
WO 2006104677A2 · 2006 [cited by applicant]
WO 2006105021A2 · 2006 [cited by applicant]
WO 2006121991A2 · 2006 [cited by applicant]
WO 2006133396A2 · 2006 [cited by applicant]
WO 2007001459A2 · 2007 [cited by applicant]
WO 2007005874A2 · 2007 [cited by applicant]
WO 2007039818A2 · 2007 [cited by applicant]
WO 2007067991A2 · 2007 [cited by applicant]
WO 2007082154A2 · 2007 [cited by applicant]
WO 2008067283A2 · 2008 [cited by applicant]
WO 2008071447A2 · 2008 [cited by applicant]
WO 2008083228A2 · 2008 [cited by applicant]
WO 2008083239A2 · 2008 [cited by applicant]
WO 2008154333A2 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO 2009009116 · 2009 [cited by applicant]
WO 2009036379A2 · 2009 [cited by applicant]
WO 2009073533A2 · 2009 [cited by applicant]
WO 2010105256A1 · 2010 [cited by applicant]
WO 2011020024A2 · 2011 [cited by applicant]
WO 2011028683 · 2011 [cited by applicant]
WO 2012009568A2 · 2012 [cited by applicant]
WO 2012130831A1 · 2012 [cited by applicant]
WO 2012145493A1 · 2012 [cited by applicant]
WO 2013025779A1 · 2013 [cited by applicant]
WO 2013067492A1 · 2013 [cited by applicant]
WO 2013079174A1 · 2013 [cited by applicant]
WO 2014100439A2 · 2014 [cited by applicant]
WO 2014100483A1 · 2014 [cited by applicant]
WO 2014100823A1 · 2014 [cited by applicant]
WO 2014159835A1 · 2014 [cited by applicant]
WO 2014194293A1 · 2014 [cited by applicant]
WO 2015017600A1 · 2015 [cited by applicant]
WO 2015031667A2 · 2015 [cited by applicant]
WO 2015069770A1 · 2015 [cited by applicant]
WO 2016040724A1 · 2016 [cited by applicant]
WO 2016070001A1 · 2016 [cited by applicant]
WO WO2016137985A1 · 2016 [cited by applicant]
WO 2016168771A2 · 2016 [cited by applicant]
WO 2016197204A1 · 2016 [cited by applicant]
WO 2017011580A2 · 2017 [cited by applicant]
WO 2017015623A2 · 2017 [cited by applicant]
WO 2017019846A1 · 2017 [cited by applicant]
WO 2017048878A1 · 2017 [cited by applicant]
WO 2017058754A1 · 2017 [cited by applicant]
WO 2017079117A1 · 2017 [cited by applicant]
WO 2017106656A1 · 2017 [cited by applicant]
WO 2017129790A1 · 2017 [cited by applicant]
WO 2017147368A1 · 2017 [cited by applicant]
WO 2017149150A1 · 2017 [cited by applicant]
WO 2017201502A1 · 2017 [cited by applicant]
WO 2018049474A1 · 2018 [cited by applicant]
WO 2018075978A1 · 2018 [cited by applicant]
WO 2018078145A1 · 2018 [cited by applicant]
WO 2018098363A2 · 2018 [cited by applicant]
WO 2018106862A1 · 2018 [cited by applicant]
WO 2018106864A1 · 2018 [cited by applicant]
WO 2019040780A1 · 2019 [cited by applicant]
WO 2019165075A1 · 2019 [cited by applicant]
WO 2019165077A1 · 2019 [cited by applicant]
WO 2019169212A1 · 2019 [cited by applicant]
WO 2020081497A1 · 2020 [cited by applicant]
Freshwater et al, 2017. Journal for Immunotherapy of Cancer: 5:43; 9 pages as printed. [cited by examiner]
Abadi et al., Host B7x promotes pulmonary metastasis of breast cancer, J. Immun., 190(7):3806-3814 (2013). [cited by applicant]
Abdiche et al., Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms, mAbs, 8:264-277 (2016). [cited by applicant]
Abdiche et al., Exploring blocking assays using octet, prote on, and biacore biosensors, Analytical Biochem., 386(2):172-180 (2009). [cited by applicant]
Al-Lazikani et al., Standard conformations for the canonical structures of Immunoglobulins, J. Mol. Biol., 273:927-948 (1997). [cited by applicant]
Ames et al., Conversion of murine fabs isolated from a combinatorial phage display library to full length immunoglobulins, J. Immunol. Methods, 184(2):177-186 (1995). [cited by applicant]
Anderson et al., Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study, J. Natl. Cancer Institute, 102(1):26-38 (2010). [cited by applicant]
Arigami et al., Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis, J. Surgical Oncology, 102:748-752 (2010). [cited by applicant]
Arnold et al., The impact of glycosylation on the biological function and structure of human Immunoglobulins, Ann. Rev. Immun., 25: 21-50 (2007). [cited by applicant]
ATCC Catalog No. PTA-5180—Mouse hybridoma: Ovr110 A57.1, 2 pages. [cited by applicant]
Ausubel et al., Current protocols in molecular biology, Greene publishing and wiley interscience, New York, TOC, 7 (1987). [cited by applicant]
Awadallah et al., Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct, Pancreas, 36(2):200-6 (2008). [cited by applicant]
Azuma et al., Potential role of decoy b7-h4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data, PLOS Medicine, 6(10):1-15, e1000166, Public Library of Science, United States (2009). [cited by applicant]
Balwit et al., The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program, J. Translational Medicine, 9:18 (2011). [cited by applicant]
Barach et al., Tcell conihibition in prostate cancer: new immune evasion pathways and emerging therapeutics, Trends Mol. Med., 17(1):47-55 (2011). [cited by applicant]
Boyd et al., Deep sequencing and human antibody repertoire analysis, Current Opinion in Immunology, 40:103-109 (2016). [cited by applicant]
Bregar et al., Characterization of immune regulatory molecules b7-h4 and pd-l1 in low and high grade endometrial tumors, Gynecologic Oncology, 145(3):446-452 (2017). [cited by applicant]
Bricogne, Bayesian statistical viewpoint on structure determination: basic concepts and examples, Meth. Enzymol., 276:361-423 (1997). [cited by applicant]
Bricogne, Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives, Acta. Crystallogr D. Biol. Crystallogr., D49(Pt 1):37-60 (1993). [cited by applicant]
Brinkman et al., Phage display of disulfide-stabilized fv fragments, J. Immunol. Methods, 182:41-50 (1995). [cited by applicant]
Burton et al., Human antibodies from combinatorial libraries, Advances in Imnunology, 57:191-280 (1994). [cited by applicant]
Carreno et al., Therapeutic opportunities in the b7/cd28 family of ligands and receptors, Current Opinion in Pharmacology, 5(4):424-430 (2005). [cited by applicant]
Champe et al., Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a, J. Biol. Chem., 270:1388-1394 (1995). [cited by applicant]
Chayen, The role of oil in macromolecular crystallization, Structure, 5(10):1269-1274 (1997). [cited by applicant]
Chen et al., Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists, BMC Cancer, 17(1):652 (2017). [cited by applicant]
Chen et al., B7-H4 Expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma, Cancer Immunology Immunotherapy, 60(7):1047-1055 (2011). [cited by applicant]
Chen et al., Increase of circulating B7-H4-expressing CD68+macrophage correlated with clinical stage of lung carcinomas, J. Immunotherapy, 35(4):354-358 (2012). [cited by applicant]
Chen et al., Increased B7-H4 Expression during esophageal squamous cell carcinogenesis is associated with IL-6/STAT3 signaling pathway activation in mice, Oncology Letters, 13(4):2207-2215 (2017). [cited by applicant]
Chen et al., Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape, Cancer Letters, 317(1):99-105 (2012). [cited by applicant]
Chen et al., Nuclear localization of B7-H4 in pulmonary adenocarcinomas presenting as a solitary pulmonary nodule, Oncotarget, 7(36):58563-58568 (2016). [cited by applicant]
Chen et al., Overexpression of B7-H4 in Tumor infiltrated dendritic cells, J. Immun. Immunochemistry, 32(4):353-364 (2011). [cited by applicant]
Chen et al., The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer, Onco. Targets and Therapy, 7:1465-1472 (2014). [cited by applicant]
Cheung et al., Epitope-specific antibody response to the surface antigen of duck hepatitis b virus in infected ducks, Virology, 176(2):546-552 (1990). [cited by applicant]
Chinnadurai et al., B7-H4 Mediates inhibition of T cell responses by activated murine hepatic stellate cells, Hepatology, 52(6):2177-2185 (2010). [cited by applicant]
Choi et al., Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family, J. Immunology, 171(9):4650-4654 (2003). [cited by applicant]
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, J. Moi. Biol., 196(4):901-917 (1987). [cited by applicant]
Chothia et al., Structural repertoire of the human VH segments, J. Mol. Biol., 227(3):799-817 (1992). [cited by applicant]
Chumsae et al., Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody, Analytical Chemistry, 86(18):8932-8936 (2014). [cited by applicant]
Clackson et al., Making antibody fragments using phage display libraries, Nature, 352:624-628 (1991). [cited by applicant]
Coales et al., Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatography and mass spectrometry, Rapid Commun. Mass Spectrom., 23(5):639-647 … [cited by applicant]
Cockett et al., High level expression of tissue inhibitor of metalloproteinases in chinese hamster ovary cells using glutamine synthetase gene amplification, Bio/Technology, 8(7):662-667 (1990). [cited by applicant]
Conroy et al., Antibodies: From novel repertoires to defining and refining the structure of biologically important targets, Methods, 116:12-22 (2017). [cited by applicant]
Cui et al., B7-H4 is predictive of poor prognosis in patients with gastric cancer, Med. Sci. Monitor, 22:4233-4237 (2016). [cited by applicant]
Cunningham et al., High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis, Science, 244:1081-1085 (1989). [cited by applicant]
D'Aria et al., Abstract# 1601: B7-H4 (DD-O110) is overexpressed in endocervicai adenorcarcinoma in situ and invasive adenocarcinoma, Cancer Research, retrieved from https//cacerres.aacrjournals.org/content/59/9_Suppleme… [cited by applicant]
Dall'Acqua et al., Properties of human IgG1s engineered for enhanced binding to the neonatal Fe receptor (FcRn), J. Biol. Chem., 281(33):23514-23524 (2006). [cited by applicant]
Damschroder et al., Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies, Molecular Immunology, 41:985-1000 (2004). [cited by applicant]
Dangaj et al., Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses, Oncolmmunology, 2:8 e25913 (2013). [cited by applicant]
Dangaj et al., novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate t-cell antitumor responses, Cancer Research, 73(15):4820-4829 (2013). [cited by applicant]
Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII, Biotechno… [cited by applicant]
Driessens et al., Costimulatory and coinhibitory receptors in anti-tumor immunity, Immunol. Rev., 229(1):126-144 (2009). [cited by applicant]
Li et al., Progress in molecular typing of triple negative breast cancer, Journal of New Medicine, No. 2 (2018). [cited by applicant]
Wang et al., B7-H4 Overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer, Cancer Cell International, 18:100 (2018). [cited by applicant]
Wang et al., Could B7-H4 serve as a target to activate anti-cancer immunity? International Immunopharmacology, 38: 97-103 (2016). [cited by applicant]
Wang et al., Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma, Tumour Biology, Online Publication, Springer Publishing, United States 1-11 (2015). [cited by applicant]
Wilcox et al., CD14+ hla-DR-/Lo Myeloid-derived suppressor cens express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma, Blood, 114(22):464, 2020, 6 (2009). [cited by applicant]
Wu et al., Abstract 547: Development of antigen-targeted vaccines and immune checkpoint inhibitors for cancer therapy, immune response modifiers: Cancer Vaccines, 1 (No Date). [cited by applicant]
Xu et al., Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FAGS-based, high-throughput selection and analytical tool, PEDS, (26)10: 663-70 (2013). [cited by applicant]
Xu et al., B7-H3 and B7-H4 Are independent predictors of a poor prognosis in patients with pancreatic cancer, Oncol. Letters, 11(3):1841-1846 (2016). [cited by applicant]
Yamane-Ohnuki et al., Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity, Wiley I… [cited by applicant]
Ye et al., Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: a systematic review and prisma-compliant meta-analysis, Medicine, 97(32):e11821 (2018). [cited by applicant]
Zang et al., B7-H3 and B7x Are highly expressed in human prostate cancer and associated with disease spread and poor outcome, Proc. Natl. Acad. Sci., 104(49):19458-19463 (2007). [cited by applicant]
Zang et al., B7x: a Widely expressed B7 family member that inhibits T cell activation, Proc. Natl. Acad. Sci., 100(18):10388-10392 (2003). [cited by applicant]
Zhang et al., B7-H4 Promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival, Oncotarget, 8(12):18861-18871 (2017). [cited by applicant]
Zhang et al., Circulating B7-H4 in serum predicts prognosis in patients with hepatocellular carcinoma, Genetics and Molecular Research, 14(4):13041-13048 (2015). [cited by applicant]
Zhang et al., Preparation and characterization of monoclonal antibody against human B7-H4 molecule, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 33(4):270-274 (2014). [cited by applicant]
Zhang et al., The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus, Oncogene, 32(46): 5347-5358 (2013). [cited by applicant]
Zhou et al., Silencing of B7-H4 suppresses the tumorigenicity of the Mgc-803 human gastric cancer cell line and promotes cell apoptosis via the mitochondrial signaling pathway, Int. J. Oncology, 52(4):1267-1276 (2018). [cited by applicant]
Zhou et al., Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors, Cell, 161:1280-1292 (2015). [cited by applicant]
Zhu et al., B7-H4 Expression is associated with cancer progression and predicts patient survival in human thyroid cancer, Asian Pacific J. Cancer Prevention, 14(5):3011-3015 (2013). [cited by applicant]
Zou, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nature Reviews, 5:263-274 (Apr. 2005, e-pub. Mar. 18, 2015). [cited by applicant]
Arosio, P. et al, Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates, Pharm Res., 30(3): 641-54 (2013). [cited by applicant]
Caldas et al. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen, Mol. Immunol., 39(15):941-952 (2003). [cited by applicant]
Casadevall et al., Immunoglobulin isotype influences affinity and specificity, Proceedings of the National Academy of Sciences, 109(31):12272-12273 (2012). [cited by applicant]
Daugherty et al., “Chapter 8: Formulation and delivery issues for monoclonal antibody therapeutics”, Curr. Tren. in Mon. Ant. Dev. Man., 103-129 (2010). [cited by applicant]
Du et al., Molecular Basis of Recognition of Human Osteopontin by 23C3, a Potential Therapeutic Antibody for Treatment of Rheumatoid Arthritis, Journal of Molecular Biology, 382(4):835-842 (2008). [cited by applicant]
Hyungjun J. et al., Structure and Cancer Immunotherapy of the B7 Family Member B7x, Cell Reports, Elesvier Ind., 9(3): 1089-1098 (2014). [cited by applicant]
Kunik et al., Structural Consensus among Antibodies Defines the Antigen Binding Site, PLOS Computational Biology, 8(2):e1002388 (2012). [cited by applicant]
Pozsgai, E., et al., β-Sarcoglycan Gene Transfer Leads to Functional Improvement in a Model of LGMD2E (S61.002), Neurology, 82(10):1-3 (2014). [cited by applicant]
Stanton et al., Clinical significance of tumor-infiltrating lymphocytes in breast cancer, J. Immunotherapy Cancer, 4:59 (2016). [cited by applicant]
Shimazaki, Japanese Journal of Zootechnical Science, 61(7): 655-660 (1990). [cited by applicant]
Wang et al., Antibody Structure, Instability, and Formulation, Journal of Pharmaceutical Sciences, 96(1):1-26 (2007). [cited by applicant]
Presta et al., Engineering therapeutic antibodies for improved function, Biochemical Society Transactions, 30(4):487-490 (2002). [cited by applicant]
Qian et al., B7-H4 Expression in various tumors determined using a novel developed monoclonal antibody, Clinical and Experimental Medicine, 11(3):163-170 (2011). [cited by applicant]
Qian et al., Development of a novel monoclonal antibody to B7-H4: characterization and biological activity, European Journal of Medical Research, 16(7):295-302 (2011). [cited by applicant]
Rabinovich et al., Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol., 25:267-296 (2007). [cited by applicant]
Rader et al., A phage display approach for rapid antibody humanization: designed combinatorial v gene libraries, PNAS., 95:8910-8915 (1998). [cited by applicant]
Rahbar et al., B7-H4 Expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity, Cancer Immunology Research, 3(2):184-195 (2015). [cited by applicant]
Rahbar et al., B7-H4 is a positive regulator of antitumor immunity, Oncoimmunology, 5(1):e1050575 (2016). [cited by applicant]
Raju, Glycosylation variations with expression systems and their impact on biological activity of therapeutic Immunoglobulins, BioProcess International, 1(4):44-53 (2003). [cited by applicant]
Riechmann et al., Reshaping human antibodies for therapy, Nature, 332:323-329 (1988). [cited by applicant]
Roguska et al., A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing, Protein Eng., 9(10):895-904 (1996). [cited by applicant]
Roguska et al., Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc. Natl. Acad. Sci. USA, 91(3):969-973 (1994). [cited by applicant]
Routier et al., Tile glycosylation pattern of a humanized IgGI antibody (01 .3) expressed in CHO cells, Glycoconjugate Journal, 14:201-207 (1997). [cited by applicant]
Roversi et al., Modelling prior distributions of atoms for macro-molecular refinement and completion, Acta. Crystallogr. D. Biol. Crystallogr., 56(Pt 10):1316-1323 (2000). [cited by applicant]
Sadun et al., Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy, Cancer Therapy: Preclinical, 13(13):4016-4025 (2007). [cited by applicant]
Salceda et al., The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation, Experimental Cell Research, 306(1):128-141 (2005). [cited by applicant]
Sambrook et al., Molecular cloning: a laboratory manual, 3rd edition, J.F. Sambrook and D.W. Russell, ed., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2:107 (2001). [cited by applicant]
Sankin et al., The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1, Urologic Oncology, 36(10):459-468 (2018). [cited by applicant]
Schalper et al., Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer, Clin. Cancer Research, 23(2):370-378 (2017). [cited by applicant]
Seliger et al., 'The complex role of B7 molecules in rumor immunology., Trends Mol. Med., 14(12):550-559 (2008). [cited by applicant]
Shaffer et al., Dissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H 4 and PD-L1, Journal for Immunotherap… [cited by applicant]
Sheehan et al., Phage and yeast display, Microbiol. Spectr., 3(1):AID-0028-2014 (2015). [cited by applicant]
Shen et al., B7-H4 Is a prognostic biomarker for poor survival in patients with pancreatic cancer, Human Pathology, 66:79-85 (2017). [cited by applicant]
Shi et al., Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer, World Journal of Surgical Oncology, 12:188 (2014). [cited by applicant]
Shields et al., High resolution mapping of the binding site on human IgG1 for FcyRI, FcyII. FcyIII, and FcRn and design of IgG1 variants with improved binding to the FcyR, J. Biol. Chem., 276(9):6591-6604 (2001). [cited by applicant]
Shields et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcyRIII and antibody-dependent cellular toxicity, J. Biol. Chem., 277:26733-26740 (Jul. 26, 2002, e-pub. May 1, 2002). [cited by applicant]
Shinkawa et al., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyto… [cited by applicant]
Shrestha et al., Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma, Frontiers in Oncology, 8:269 (2018). [cited by applicant]
Sica et al., B7-H4, a Molecule of the B7 family, Negatively regulates T cell immunity, Immunity, 18(6):849-861 (2003). [cited by applicant]
Siegel et al., High efficiency recovery and epitope-specific sorting of an scFv yeast display library, J. Immunol. Methods, 286(1-2):141-153, (2004). [cited by applicant]
Simon et al., B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer, Cancer Research, 66(3):1570-1575 (2006). [cited by applicant]
Simon et al., B7-H4 Is over-expressed in early-stage ovarian cancer and is independent of CA125 expression, Gynecologic Oncology, 106(2):334-341 (2007). [cited by applicant]
Simon et al., Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue and serum of ovarian cancer patients, Cancer Research, Abstract 4882, retrieved from https://cancerres.aacrjournals.org/content/65/9_Supplemen… [cited by applicant]
Smith et al., B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look, Gynecologic Oncology, 134(1):181-189 (2014). [cited by applicant]
Smith et al., Mouse model recapitulating human fey receptor structural and functional diversity, PNAS, 109(16):6181-6186 (Apr. 17, 2012, e-pub. Apr. 2, 2012). [cited by applicant]
Smith et al., Tumor regression and delayed onset toxicity following B7-H4 car T cell therapy, Mol. Therapy, 24(11):1987-1999 (2016). [cited by applicant]
Song et al., Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis, Oncotarget, Advance Publications:1-11, Impact Journals, United States (2016). [cited by applicant]
Sood, PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer, Immunol. Res., 46:206-215 (2010, e-pub. Sep. 10, 2009). [cited by applicant]
Sun et al., B7-H3 and B7-H4 expression in non-small-cell lung cancer, Lung Cancer, 53(2):143-151 (2006). [cited by applicant]
Tan et al., Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis, Oncotarget, 8(16):27137-27144 (2017). [cited by applicant]
Terrett et al., Preclinical development of anti B7-H4 therapeutic antibodies, Cancer Research, Abstract 4986, retrieved from https://canerres.accrjournals.org/content/68/9 Supplement/4986, last visited Apr. 30, 2020, 3 … [cited by applicant]
Thompson et al., B7-H1, Glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma., Urology, 66(Suppl. 5A):10-14 (2005). [cited by applicant]
Thompson et al., Serum-soluble B7x Is elevated in renal cell carcinoma patients and is associated with advanced stage, Cancer Research, 68(15):6054-6058 (2008). [cited by applicant]
Tramontano et al., Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the vh domains of Immunoglobulins, J. Mol. Biol., 215(1):175-182 (1990). [cited by applicant]
Tringler et al., B7-H4 is highly expressed in ductal and lobular breast cancer, Clinical Cancer Research, 11(5):1842-1848 (2005). [cited by applicant]
Tringler et al., B7-H4 overexpression in ovarian tumors, Gynecologic Oncology, 100(1):44-52 (2006). [cited by applicant]
Umana et al., Engineered glycoforms of an antineuro-Biastoma IgG 1 with optimized antibody-dependent cellular cytotoxic activity, Nat. Biotechnol., 17:176-180 (1999). [cited by applicant]
Van Regenmortel, MHV., Development of a preventive HIV vaccine requires solving inverse problems which is unattainable by rational vaccine design, Front. Immunol., 8:2009 (2018). [cited by applicant]
Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity, Science, 239(4857):1534-1536 (1988). [cited by applicant]